Vectura Group

From Wikipedia, the free encyclopedia
Vectura Group plc
Type Public (LSE: VEC)
Industry Pharmaceuticals
Founded 1997
Headquarters Chippenham, UK
Key people Jack Cashman, Chairman
Christopher Blackwell, (CEO)
Revenue £25.2 million (2008)
Operating income £(25.1) million (2008)
Net income £(19.2) million (2008)
Website www.vectura.com

Vectura Group plc is a leading British-based pharmaceuticals business. It is based in Chippenham and is a former constituent of the FTSE 250 Index.

History

Vectura was formed in 1997 with venture finance backing. In 1999 it acquired Co-ordinated Drug Development and the Centre for Drug Formulation Studies. In 2002 it acquired inhaler technology and an associated engineering team from Cambridge Consultants.[1]

In 2004 it was listed on the Alternative Investment Market.[1] In 2007 it acquired Innovata plc, a developer of pulmonary products,[1][2] and then moved on the full list of the London Stock Exchange.[1]

Operations

The Group specialises in inhalation technology and currently has two main focuses:

  • Respiratory: inhaled products for asthma and COPD
  • Neurology: products for Parkinson's Disease and migraine

References

External links


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.